B2C Consumer App / Platform
Hims & Hers vs SelectQuote
Structured technology and market comparison · 2026
Direct Feature Comparison
Hims & Hers · vs · SelectQuoteConsumer telehealth platform with subscription-based treatment and fulfilment.
Direct-to-consumer insurance distribution and senior healthcare platform.
Analyze all overlapping signals and tech stacks for Hims & Hers and SelectQuote
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Hims & Hers and SelectQuote?
When comparing Hims & Hers and SelectQuote, both platforms operate within the B2C Consumer App / Platform ecosystem. Hims & Hers is positioned as Consumer telehealth platform with subscription-based treatment and fulfilment, whereas SelectQuote focuses on Direct-to-consumer insurance distribution and senior healthcare platform. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Hims & Hers and SelectQuote?
When evaluating Hims & Hers and SelectQuote, enterprise buyers also consider other platforms in B2C Consumer App / Platform. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Hims & Hers and SelectQuote compare?
Hims & Hers is headquartered in US (founded in 2017) with 1,001–5,000 employees. SelectQuote is based in US (founded in 1984) with 1,001–5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Hims & Hers vs SelectQuote
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Hims & Hers
Recent Signals
- ·PR Newswire: Advertising & MarketingPrivacy
Hims & Hers Securities Class Action Deadline Nov 2, 2026
Robbins Geller Rudman & Dowd LLP announces a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) for alleged violations of the Securities Exchange Act. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to seek lead plaintiff appointment. The lawsuit follows an FTC complaint alleging Hims & Hers shared sensitive health information with third-party advertising platforms like Meta and Snap, and misled consumers about billing. The stock dropped nearly 15% upon the FTC news. Lead plaintiff process outlined under the Private Securities Litigation Reform Act.
- FTC filed a lawsuit against Hims & Hers on July 29, 2026, alleging sharing of sensitive health data with advertising platforms.
- Hims & Hers stock declined nearly 15% following the FTC announcement.
- Robbins Geller Rudman & Dowd LLP filed a class action lawsuit (Velanki v. Hims & Hers Health, Inc.) in the Northern District of California.
- ·SEC APIfinancials
10-Q Financial Filing Analysis for Hims & Hers (2026-08-10)
Hims & Hers reported Q2 2026 revenue of $753.2 million, up 38% year-over-year, and six-month revenue of $1.36 billion (+20% YoY), driven by strong expansion in the Hers brand and international growth from acquisitions including Eucalyptus. However, the company experienced a GAAP net loss of $86.3 million for Q2 2026 (compared to net income of $42.5 million in Q2 2025), primarily impacted by a strategic transition in its U.S. GLP-1 weight loss business, non-recurring restructuring charges, increased fulfillment costs from shorter shipping cadences, and a $60 million FTC legal contingency accrual.
- Q2 2026 total revenue reached $753.21 million (+38% YoY) with ending subscribers expanding 19% YoY to 2.89 million.
- GAAP net loss was $86.29 million for Q2 2026, down from net income of $42.51 million in Q2 2025, while Adjusted EBITDA stood at $60.32 million.
- Recorded a $60.0 million legal contingency accrual related to an FTC and multi-state consumer protection lawsuit regarding subscription and cancellation practices.
- ·PR Newswire: Technology NewsPrivacy
Hims & Hers Securities Fraud Class Action Filed
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) in the U.S. District Court for the Northern District of California. The suit alleges the telehealth company disclosed sensitive health information to third-party advertising platforms, including Snap and Meta (Facebook), without proper consent, and misled consumers about billing practices. The FTC filed a related lawsuit on July 29, 2026, causing the stock to drop 14.73% to $25.00. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to apply as lead plaintiff. The case, Velanki v. Hims & Hers Health, Inc. et al., is being publicized by law firms including Kahn Swick & Foti, Kessler Topaz Meltzer & Check, and the Law Offices of Howard G. Smith.
- FTC sued Hims & Hers for sharing sensitive health data with advertising platforms (Snap, Meta) and deceptive billing practices.
- Hims & Hers stock dropped $4.32 (14.73%) to $25.00 on July 29, 2026.
- Class action lawsuit filed; lead plaintiff deadline is November 2, 2026.
SelectQuote
Recent Signals
- ·SEC APIfinancials
10-K Financial Filing Analysis for SelectQuote (2026-08-25)
SelectQuote, Inc. reported its annual financial results and business overview in its Form 10-K for the fiscal year ended June 30, 2026. The company operates a technology-driven, direct-to-consumer distribution platform for insurance policies and healthcare services, leveraging proprietary AI/ML algorithms to optimize lead acquisition and customer lifetime value (LTV). During fiscal 2026, SelectQuote accelerated strategic investments in operational AI—including contact center conversational voice systems—while intentionally expanding its Healthcare Services division (anchored by SelectRx pharmacy operations and SelectPatient Management) and de-emphasizing its Auto & Home distribution business. Top carrier partners UnitedHealthcare, Humana, and Aetna represented a combined 64% of consolidated revenues. The company also disclosed active corporate initiatives including an NYSE minimum share price deficiency notice received in March 2026, for which it is seeking shareholder approval to implement a reverse stock split, and ongoing legal defense regarding a federal False Claims Act qui tam matter.
- SelectQuote's top three carrier partners (UnitedHealthcare at 39%, Humana at 13%, and Aetna at 12%) generated 64% of total consolidated revenue in fiscal year 2026.
- For the fiscal year ended June 30, 2026, the company sold over 635,000 Senior segment policies (89% Medicare Advantage) and generated more than $200 million in new premiums across its Life and Auto & Home segments.
- SelectRx grew its active patient base to over 109,000 members as of June 30, 2026, backed by fulfillment expansion at its Olathe, Kansas facility.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Hims & Hers and SelectQuote share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks